Trial Profile
A SINGLE-DOSE, RANDOMIZED, OPEN-LABEL, TWO-WAY CROSSOVER BIOEQUIVALENCE STUDY OF TNX-102 SL (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) 2.8 mg FROM TWO MANUFACTURERS IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jul 2019
Price :
$35
*
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Agitation; Fibromyalgia; Post-traumatic stress disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Tonix Pharmaceuticals Inc
- 01 Jun 2017 New trial record